TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸ADPT

Adaptive Biotechnologies Corporation - Common Stock

NASDAQ
$27.93
▲ $3.51 (+14.4%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 20 Nov 2026
H $32.21L $12.50+117.7%
$32.21$28.27$24.33$20.38$16.44$12.5$27.93
RSI (14)
Intraday · 15-minSell-20RSI 52DowntrendMACD Bullishfor day-trading context — not advice

Technical signal

Buy+25
RSI (14)52
oversold 30overbought 70
Trend
Uptrend
MACD
Bearish
Bollinger
Within bands
vs 20-day
above
vs 50-day
above
vs 200-day
above
Support
$24.80
Resistance
$32.21
  • Price is above its 50-day average (medium-term uptrend).
  • Price is above its 200-day average (long-term uptrend).

Signal backtest · 2026-02-20 → 2026-11-20

Strategy return
+64.0%
Buy & hold
+83.8%
Trades
4
Win rate
25%

$100,000.00 invested would be worth $164,038.30 (+64.0%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Adaptive Biotechnologies Corporation· Diagnostics & Research

source: yahoo

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Sector
Healthcare
Industry
Diagnostics & Research
Employees
624
Headquarters
Seattle, United States
www.adaptivebiotech.com ↗

Fundamentals

No fundamental data is currently available for this listing from our data providers.

Recent news

News sentiment:▲ Positive3↑ · 0↓ · 5–
  • FDA Grants Priority Tag to AZN's BLA Filing for Gastric Cancer Drug— Neutral
    Zacks · 20 Nov 2026
  • Adaptive Biotechnologies (ADPT) Stock Sees Fair Value Lift After Q3 Analyst Revisions— Neutral
    Simply Wall St. · 20 Nov 2026
  • Should ASH ClonoSEQ Data Require Action From Adaptive Biotechnologies (ADPT) Investors?— Neutral
    Simply Wall St. · 20 Nov 2026
  • Is Adaptive Biotechnologies (ADPT) Priced For Perfection After Its Run?
  • MACD just crossed bearish (momentum turning down).
  • Educational technical indicators — not investment advice. TradeOrgs does not place trades.

    — Neutral
    Simply Wall St. · 20 Nov 2026
  • Sanofi's Next-Generation Rabies Vaccine Secures Approval in EU▲ Positive
    Zacks · 19 Nov 2026
  • SNY Wins FDA Approval for Infilbray in Type 3 Gaucher Disease▲ Positive
    Zacks · 19 Nov 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.